4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0001209191-21-050256
Chief Executive Officer sold 30,000 shares at an average $128.78 ($3,863,469)
- Chief Executive Officer acquired 30,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kulkarni Samarth Chief Executive Officer | 2021-08-04 | Option exercise | +1,500 | $12.57 | $18,855 | 189,219 | D |
| Kulkarni Samarth Chief Executive Officer | 2021-08-04 | Sale | −1,500 | $125.02 | $187,530 | 187,719 | D |
| Kulkarni Samarth Chief Executive Officer | 2021-08-05 | Option exercise | +28,500 | $12.57 | $358,245 | 216,219 | D |
| Kulkarni Samarth Chief Executive Officer | 2021-08-05 | Sale | −1,000 | $126.67 | $126,670 | 215,219 | D |
| Kulkarni Samarth Chief Executive Officer | 2021-08-05 | Sale | −4,700 | $127.82 | $600,754 | 210,519 | D |
| Kulkarni Samarth Chief Executive Officer | 2021-08-05 | Sale | −13,499 | $128.85 | $1,739,346 | 197,020 | D |
| Kulkarni Samarth Chief Executive Officer | 2021-08-05 | Sale | −6,819 | $129.82 | $885,243 | 190,201 | D |
| Kulkarni Samarth Chief Executive Officer | 2021-08-05 | Sale | −2,482 | $130.51 | $323,926 | 187,719 | D |
| Derivatives | |||||||
| Kulkarni Samarth Chief Executive Officer | 2021-08-04 | Option exercise · Stock Option (Right to Buy) | −1,500 | 61,833 | D | ||
| Kulkarni Samarth Chief Executive Officer | 2021-08-05 | Option exercise · Stock Option (Right to Buy) | −28,500 | 33,333 | D | ||
| Open-market sales · 30,000 sh · avg $128.78 · $3,863,469 | |||||||
Loading xslF345X03/doc4.xml…